A closer look at “Eli Lilly Launches Direct-to-Consumer Mounjaro Delivery in Australia, Bypassing Pharmacies”, exactly as the source publishes it. Eli Lilly is expanding its direct-to-consumer platform LillyDirect to Australia, offering home delivery of the diabetes and weight-loss drug Mounjaro. The move cuts out traditional pharmacies, which has drawn criticism from Australian pharmacists and doctors who worry about patient safety and the erosion of local healthcare services. LillyDirect, already operating in the U.S., allows patients to obtain prescriptions through telehealth and receive medications by mail.
In Australia, Mounjaro is approved for type 2 diabetes and has seen soaring demand for off-label weight loss use, leading to supply shortages. Pharmacists argue that bypassing them removes a critical check on drug interactions and patient counseling, while doctors express concern about fragmented care. Lilly says the model increases access and convenience, particularly for patients in rural or remote areas. For the complete material, the listing points back to the source inside the network.